Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Down 5.3% – Here’s What Happened

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) were down 5.3% on Wednesday . The stock traded as low as $30.37 and last traded at $31.07. Approximately 523,357 shares traded hands during trading, an increase of 14% from the average daily volume of 458,558 shares. The stock had previously closed at $32.81.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued a “neutral” rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday.

Supernus Pharmaceuticals Price Performance

The company has a 50-day moving average of $37.34 and a two-hundred day moving average of $35.39. The stock has a market capitalization of $1.71 billion, a PE ratio of 29.04 and a beta of 0.90.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the transaction, the vice president now owns 10,149 shares of the company’s stock, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several institutional investors have recently modified their holdings of SUPN. Barclays PLC lifted its holdings in shares of Supernus Pharmaceuticals by 88.3% during the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock worth $3,393,000 after buying an additional 51,005 shares during the last quarter. Segall Bryant & Hamill LLC acquired a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter valued at $791,000. Geode Capital Management LLC grew its holdings in Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after acquiring an additional 74,438 shares during the period. Franklin Resources Inc. grew its position in shares of Supernus Pharmaceuticals by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock worth $987,000 after buying an additional 2,121 shares during the period. Finally, Empowered Funds LLC bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at $1,498,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.